Ultragenyx pharmaceutical inc. (RARE)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Revenues:
Total revenues

103,714

51,495

2,612

133

-

-

-

-

Operating expenses:
Cost of sales

9,008

1,146

1

-

-

-

-

-

Research and development

357,355

293,998

231,644

183,204

114,737

45,967

27,829

12,641

Selling, general and administrative

161,524

127,724

99,909

64,936

33,001

10,811

4,451

3,344

Total operating expenses

527,887

422,868

331,554

248,140

147,738

56,778

32,280

15,985

Loss from operations

-424,173

-371,373

-328,942

-248,007

-147,738

-56,778

-32,280

-15,985

Interest income

13,238

9,542

4,074

3,789

2,320

608

216

1

Gain from sale of priority review vouchers

-

170,300

-

-

-

-

-

-

Change in fair value of investment in Arcturus equity securities

13,413

-

-

-

-

-

-

-

Non-cash interest expense on liability related to the sale of future royalties

1,135

-

-

-

-

-

-

-

Other income (expense), net:
Other expense

-787

-5,588

6,530

-1,621

-200

-3,632

-3,006

-350

Total other income (expense), net

-

-

-

-

2,120

-3,024

-2,790

-349

Loss before income taxes

-399,444

-197,097

-318,338

-245,839

-145,618

-59,802

-

-

Provision for income taxes

3,283

514

-16,200

35

-

-

-

-

Net loss

-402,727

-197,611

-302,139

-245,874

-145,618

-59,802

-35,070

-16,334

Shares used in computing net income (loss) per share:
Net loss attributable to common stockholders

-

-

-

-

-145,618

-64,610

-50,289

-19,561

Net loss per share, basic and diluted

-7.12

-3.97

-7.12

-6.21

-3.96

-2.25

-14.87

-14.20

Shares used in computing net loss per share, basic and diluted

56,576

49,775

42,453

39,586

36,782

28,755

3,382

1,377

Collaboration and License
Total revenues

83,493

41,693

2,136

-

-

-

-

-

Product Sales
Total revenues

20,221

9,802

476

133

-

-

-

-